Pasithea Therapeutics Corp
About
Pasithea Therapeutics Corp (NASDAQ:KTTA) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 20 2026
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
Apr 1 2026
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
Feb 17 2026
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Jan 13 2026
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
Dec 2 2025
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
Financials
Revenue
$486.56 K
Market Cap
$17.78 M
EPS
-2.91